Experienced in Ectodermal Dysplasias

Jianzhong Z. Zhang

Beijing, CN 
Experienced in Ectodermal Dysplasias
Beijing, CN 
OverviewLocationsClinical Research

Overview

Jianzhong Zhang practices in Beijing, China. Zhang is rated as an Experienced expert by MediFind in the treatment of Ectodermal Dysplasias. Their top areas of expertise are Atopic Dermatitis, Autosomal Recessive Hypotrichosis, Alopecia Areata, Osteotomy, and Sacral Nerve Stimulation.

Their clinical research consists of co-authoring 180 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Ectodermal Dysplasias.

Locations

Beijing, China
Other Locations
Handan, China
No. 11 Xizhimen South Street, Xicheng District, Xizhimen, 100044, China
No.11 Xizhimen South Street, Beijing, Xicheng, 100044, China
Congtai Road No. 81, Congtai District, Handan, 056000, China
300399 P.R. China, Tianjin, 300399, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drug: Jaktinib
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: March 14, 2025
Intervention Type: Drug
Study Drug: Jaktinib
Study Phase: Phase 3
View 1 Less Clinical Trial

180 Total Publications

Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials.
Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials.
Journal: American journal of clinical dermatology
Published: November 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhang's expertise for a condition
ConditionClose
    View All 60 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile